abstract |
The preparation and use of the compound described for treating diseases that antagonise VAP-1-mediated binding of endothelial cells to lymphocytes, of a VAP-1 binding compound such as inflammation (chronic or acute), arthritis, rheumatoid arthritis, infection, dermatosis, inflammatory bowel disease, and autoimmune diseases. |